Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer

Next Previous
Trial Profile

Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berzosertib (Primary)
  • Indications Brain metastases; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 17 Oct 2024 Planned End Date changed from 22 Sep 2024 to 22 Sep 2025.
  • 29 Sep 2023 Planned End Date changed from 24 Feb 2024 to 22 Sep 2024.
  • 25 Feb 2023 Planned End Date changed from 30 Dec 2023 to 24 Feb 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top